

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : Not Yet Assigned
Applicants : Roger D. Tung, et al.
Application No. : Not Yet Assigned
Filed : Concurrently Herewith
For : INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HEPATITIS C VIRUS NS3
PROTEASE

New York, New York
June 27, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney, make of record the documents listed below (copies enclosed herewith). A completed Form PTO-1449 listing all of the documents in alphabetical order is enclosed herewith.

United States Patents

<u>Inventor</u>	<u>Patent No.</u>	<u>Issue Date</u>
Tung et al.	6,265,380	July 24, 2001

EV133109388US

Foreign Patent Applications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Vertex	WO 95/35308	December 28, 1995
Pfizer	WO 93/25574	December 23, 1993
Merrell Dow	EP 0 363 284	April 11, 1990
Merrell Dow	EP 0 195 212	September 24, 1986

Other References

S. Mehdi et al., "*The Inhibition of Human Neutrophil Elastase and Cathepsin C by Peptidyl 1,2-Dicarbonyl Derivatives*", Biochemical and Biophysical Research Communications, 166(2), pp. 595-600 (January 30, 1990).


All of the documents listed above were cited in an International Search Report issued in connection with the counterpart PCT application PCT/US97/18968.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

In accordance with 37 C.F.R. § 1.98, submission of this Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Kyumin Lee (Reg. No. 53,195)

Agent for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas

New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
VPI96-11 CIP CON DIV2APPLN. NO.
Not Yet AssignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Roger D. Tung et al.CONFIRMATION NO.
Not Yet AssignedFILING DATE
Concurrently HerewithGROUP
Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,265,380	07/24/01	Tung et al.	514	17	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 95/35308	12/28/95	PCT	C07K	5/023		
	WO 93/25574	12/23/93	PCT	C07K	5/02		
	EP 0 363 284	04/11/90	EPO	C07K	5/02		
	EP 0 195 212	09/24/86	EPO	C07c	97/02		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	S. Mehdi et al., "The Inhibition of Human Neutrophil Elastase and Cathepsin C by Peptidyl 1,2-Dicarbonyl Derivatives", <u>Biochemical and Biophysical Research Communications</u> , 166(2), pp. 595-600 (January 30, 1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

EV133109388US